Navigation Links
Hope For Patient With Alzheimer’s Diseas

New research shows combining the drugs memantine and donepezil may improve memory in patients with Alzheimer’s disease. //

Researchers studied more than 300 patients with moderate to severe Alzheimer’s. Participants were already taking the drug donepezil when the study began. Donepezil works by preventing the breakdown of acetylcholine, a chemical messenger in the brain that is important for memory and other thinking skills.For the study, patients received either memantine or a placebo. Memantine targets glutamate, a brain chemical that is associated with nerve cell death when produced in high quantities. The Food and Drug Administration approved memantine in October 2003.

Researchers found patients who took memantine and donepezil experienced significant improvement in cognition, memory, and overall daily functioning compared to those in the placebo group. Researchers say they were pleasantly surprised to see that the two drugs worked well together. Memantine is significant, since it provides an entirely new medication option for the 2.5 million people currently suffering at the advanced stage of Alzheimer’s.

Prior to the FDA’s approval of memantine, only acetylcholinesterase inhibitors, like donepezil, were approved for treating Alzheimer’s patients. Researchers say the study is significant because this is the first time combining two Alzheimer’s drugs has shown positive results.

Researchers conclude saying , “ To find a new medication that can provide substantial benefit to patients at this stage of the disease, either alone or in combination with another Alzheimer’s drug, is certainly good news ... While memantine is not a cure for Alzheimer’s, if it helps to keep a person with Alzheimer’s at home for six months or one year longer, then it is a victoy.”

Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patient’s perception of health status helps in better recover
7. Patients often assume wrongly that they are allergic to penicillin
8. New FDA Approved Drug NATRECOR For Heart Failure Patients
9. Hemochromatosis Patients Blood is Safe
10. Fifth US Patient Receives Artificial Heart
11. Patients Pressure Would Result In Overprescription
Post Your Comments:

(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: